Sameer Doshi
Sameer Doshi
Bestätigte E-Mail-Adresse bei amgen.com
Titel
Zitiert von
Zitiert von
Jahr
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
M Zhu, B Wu, C Brandl, J Johnson, A Wolf, A Chow, S Doshi
Clinical pharmacokinetics 55 (10), 1271-1288, 2016
712016
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis
L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ...
Clinical pharmacokinetics 50 (12), 793-807, 2011
682011
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients
M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJP Ruixo, E Loh, Y Zhang
Journal of Pharmaceutical Sciences 103 (1), 328-336, 2014
642014
Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours
L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ...
Clinical pharmacokinetics 51 (4), 247-260, 2012
562012
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects
YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow
The AAPS journal 12 (4), 729-740, 2010
562010
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play …
B Agoram, K Aoki, S Doshi, C Gegg, G Jang, G Molineux, L Narhi, S Elliott
Journal of pharmaceutical sciences 98 (6), 2198-2211, 2009
422009
Rilotumumab exposure–response relationship in patients with advanced or metastatic gastric cancer
S Doshi, PO Gisleskog, Y Zhang, M Zhu, KS Oliner, E Loh, JJP Ruixo
Clinical Cancer Research 21 (11), 2453-2461, 2015
362015
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
M Zhu, R Tang, S Doshi, KS Oliner, S Dubey, Y Jiang, RC Donehower, ...
British journal of cancer 112 (3), 429-437, 2015
352015
Impact of target‐mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9)
JP Gibbs, S Doshi, M Kuchimanchi, A Grover, MG Emery, MG Dodds, ...
The Journal of Clinical Pharmacology 57 (5), 616-626, 2017
262017
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
DJ Freeman, K McDorman, S Ogbagabriel, C Kozlosky, BB Yang, S Doshi, ...
Molecular Cancer 11 (1), 1-11, 2012
252012
Exposure‐response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis
S Doshi, A Chow, JJP Ruixo
The Journal of Clinical Pharmacology 50 (S9), 75S-90S, 2010
242010
Denosumab dose selection for patients with bone metastases from solid tumors
S Doshi, L Sutjandra, J Zheng, W Sohn, M Peterson, G Jang, AT Chow, ...
Clinical Cancer Research 18 (9), 2648-2657, 2012
192012
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents
S Doshi, W Krzyzanski, S Yue, S Elliott, A Chow, JJ Pérez-Ruixo
Clinical pharmacokinetics 52 (12), 1063-1083, 2013
152013
Blinatumomab pharmacodynamics and exposure–response relationships in relapsed/refractory acute lymphoblastic leukemia
M Zhu, A Kratzer, J Johnson, C Holland, C Brandl, I Singh, A Wolf, ...
The Journal of Clinical Pharmacology 58 (2), 168-179, 2018
112018
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Y Zhang, S Doshi, M Zhu
British journal of clinical pharmacology 80 (5), 957-964, 2015
112015
Romiplostim dose–response in patients with myelodysplastic syndromes
JJ Perez Ruixo, S Doshi, YMC Wang, DR Mould
British journal of clinical pharmacology 75 (6), 1445-1454, 2013
92013
Romiplostim dose response in patients with immune thrombocytopenia
JJ Perez‐Ruixo, B Green, S Doshi, YM Wang, DR Mould
The Journal of Clinical Pharmacology 52 (10), 1540-1551, 2012
92012
Exposure-response (ER) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or …
M Zhu, R Tang, S Doshi, KS Oliner, S Kathman, PO Gisleskog, S Dubey, ...
Journal of Clinical Oncology 30 (15_suppl), 2535-2535, 2012
82012
Pharmacokinetics of epratuzumab administered as a single agent or in combination with rituximab in patients with B-cell NHL
B Perotti, S Doshi, D Chen, U Gayko, JP Leonard, WA Wegener, ...
Proc Am Soc Clin Oncol 22, 575, 2003
82003
Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications
SM Wasserman, MS Sabatine, MJ Koren, RP Giugliano, JC Legg, ...
Journal of cardiovascular pharmacology and therapeutics 23 (5), 423-432, 2018
72018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20